Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Loses Oversight Of Yaz DTC Ads Under Agreement With States Attorneys General

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has oversight over DTC advertising for Bayer’s Yaz contraceptive after the company violated an earlier agreement with state attorneys general.

You may also be interested in...



DTC Held Hostage? FDA Pre-Review of TV Ads May Delay Rx Campaigns

FDA is proposing changes to its regulation of television advertising for prescription drugs with a mandatory pre-review of ads for certain products. The agency says it has the resources to complete all reviews on time. But stakeholders worry that the draft requirements would delay campaigns and make DTC advertising more expensive. It’s not like there’s a good alternative: jumping the gun on DTC carries its own set of risks.

Bayer Tries Google Format To Keep Yaz Name In Sponsored Link And Meet Risk Requirements

The sponsored Google search result for Yaz gives no indication and links user to "full safety and prescribing information, including a boxed warning."

Bayer Tries Google Format To Keep Yaz Name In Sponsored Link And Meet Risk Requirements

The sponsored Google search result for Yaz gives no indication and links user to "full safety and prescribing information, including a boxed warning."

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel